Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CISATRACURIUM
GlaxoSmithKline (Ireland) Limited
M03AC11
CISATRACURIUM
2 Mg/Ml
Solution for Inj/Inf
Product subject to prescription which may not be renewed (A)
Other quaternary ammonium compounds
Authorised
2000-08-07
Reason for update: Removal of 2.5 ml pack size HPRA Approval Date: Text Date: 3/5/16 Text Issue and Draft No.: Issue 3 Draft 2 CO Number: (GSK LOGO) PACKAGE LEAFLET: INFORMATION FOR THE USER NIMBEX® 2 MG/ML SOLUTION FOR INJECTION/INFUSION cisatracurium READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Nimbex is and what it is used for 2. What you need to know before you are given Nimbex 3. How Nimbex is given 4. Possible side effects 5. How to store Nimbex 6. Contents of the pack and other information 1. WHAT NIMBEX IS AND WHAT IT IS USED FOR Nimbex contains a medicine called cisatracurium. This belongs to a group of medicines called muscle relaxants. Nimbex is used: - to relax muscles during operations on adults and children over 1 month of age, including heart surgery - to help insert a tube into the windpipe (tracheal intubation), if a person needs help to breathe - to relax the muscles of adults in intensive care. Ask your doctor if you would like more explanation about this medicine. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN NIMBEX DO NOT USE NIMBEX: - if you are allergic to cisatracurium, any other muscle relaxant or any of the other ingredients of Nimbex (listed in section 6) - if you have reacted badly to an anaesthetic before Do not have Nimbex if any of the above apply to you. If you are not sure, talk to your Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nimbex 2mg/ml solution for injection/infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Cisatracurium 2 mg as cisatracurium besilate 2.68 mg per 1ml. One ampoule of 2.5 ml contains 5 mg of cisatracurium One ampoule of 5 ml contains 10 mg of cisatracurium One ampoule of 10 ml contains 20 mg of cisatracurium One ampoule of 25 ml contains 50 mg of cisatracurium For the full list of excipients, see Section 6.1. 3 PHARMACEUTICAL FORM Solution for Injection/infusion. Colourless to pale yellow or greenish yellow solution. Practically free from visible particulate matter. 4 CLINICAL PARTICULARS Nimbex is an intermediate-duration, non-depolarising neuromuscular blocking agent for intravenous administration. 4.1 THERAPEUTIC INDICATIONS Nimbex is indicated for use during surgical and other procedures in adults and children aged 1 month and over. Nimbex is also indicated for use in adults requiring intensive care. Nimbex can be used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU) to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Nimbex should be only administered by or under the supervision of anaesthetists or other clinicians who are familiar with the use and action of neuromuscular blocking agents. Facilities for tracheal intubation, and maintenance of pulmonary ventilation and adequate arterial oxygenation have to be available. Please note that Nimbex should not be mixed in the same syringe or administered simultaneously through the same needle as propofol injectable emulsion or with alkaline solutions such as sodium thiopentone. (see section 6.2). Nimbex contains no antimicrobial preservative and is Read the complete document